Health & BioTech
Why the TrumpRx Expansion Could Change How Some Patients Shop for Prescriptions
The Trump administration has added more than 600 generic medicines to TrumpRx, its direct-to-consumer prescription website, and that change could make the platform more useful...
Instil Bio’s Pivot from Setbacks to Strategic Partnerships
Instil Bio, Inc. (NASDAQ: TIL), a small-cap biotech based in Dallas, has always lived on two timelines. The first is the steady grind of clinical...
How Data and Dollars Extend a Drug’s Journey
Hidradenitis suppurativa, or HS, affects about 1% of people worldwide, causing painful lumps, abscesses, and scarring in areas like the armpits and groin. This chronic...
CeriBell – Navigating Neurological Diagnostics Challenges
When patients arrive at a hospital with unexplained confusion or altered mental states, doctors often face a tough puzzle. Many of these cases stem from...
Coya Therapeutics Moves Closer to an ALS Treatment with FDA Fast Track
It is not a household name, but Coya Therapeutics, Inc. (NASDAQ: COYA) sits in the middle of a growing effort to treat neurodegenerative and autoimmune...
Longeveron and the Promise of Stem Cells for Frailty and HLHS
In the last decade, stem cell therapies have moved from futuristic promise to a serious area of research focused on some of medicine’s hardest problems,...
MoonLake Immunotherapeutics Clears Key FDA Hurdle in Psoriasis Fight
Autoimmune diseases like psoriasis affect millions around the world. These conditions cause the immune system to attack healthy tissues, leading to painful inflammation, scaly skin...
Specialty Pharma Growth Gives ANI Pharmaceuticals More Room to Raise Expectations
A stronger outlook can sometimes matter more than a single quarter, and that was the message from ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). After reporting first...
Funding a Path Forward in Neurodegenerative Biotech
When small biotechnology companies need money to keep their work going, they often turn to selling shares. One recent example involves a firm working on...
Telomir Pharmaceuticals’ FDA Milestone in Triple-Negative Breast Cancer
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) has cleared one of the more nerve-wracking hurdles in the drug-development calendar: the U.S. Food and Drug Administration has cleared...
